

DAFTAR PUSTAKA

1. Monroy-Sosa, A., Chakravarthi, S. S., de La Garza-Salazar, J. G., Meneses, A., Amin, G., & Kassam, B. (2021). *Brain & Skull Base Principles of Neuro-Oncology*. https://doi.org/https://doi.org/10.1007/978-3-030-54879-7_2
2. Lapointe, S., Perry, A., & Butowski, N. A. (2018). Primary brain tumours in adults. In *The Lancet* (Vol. 392, Issue 10145, pp. 432–446). Lancet Publishing Group. [https://doi.org/10.1016/S0140-6736\(18\)30990-5](https://doi.org/10.1016/S0140-6736(18)30990-5)
3. Buerki, R. A., Horbinski, C. M., Kruser, T., Horowitz, P. M., James, C. D., & Lukas, R. v. (2018). An overview of meningiomas. In *Future Oncology* (Vol. 14, Issue 21, pp. 2161–2177). Future Medicine Ltd. <https://doi.org/10.2217/fon-2018-0006>
4. Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. *Neuro-Oncology*, 21(Suppl 5), v1–v100. <https://doi.org/10.1093/neuonc/noz150>
5. Widodo, D., Ihwan, A., & Arungpadang, M. P. (2020). Evaluasi kasus meningioma di Rumah Sakit Wahidin Sudirohusodo Makassar tahun 2012-2018. *Intisari Sains Medis*, 11(3), 1345–1348. <https://doi.org/10.15562/ism.v11i3.767>
6. Damayanti, A. A., Kalanjati, V. P., & Wahyuhadi, J. (2022). Korelasi Usia dan Jenis Kelamin dengan Angka Kejadian Meningioma. *AKSONA*, 1(1), 34–38. <https://doi.org/10.20473/aksona.v1i1.99>
7. Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathologica*, 131(6), 803–820. <https://doi.org/10.1007/s00401-016-1545-1>
8. Gritsch, S., Batchelor, T. T., & Gonzalez Castro, L. N. (2022). Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. *Cancer*, 128(1), 47–58. <https://doi.org/10.1002/cncr.33918>
9. Torp, S. H., Solheim, O., & Skjulsvik, A. J. (2022). The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know—a minireview. *Acta Neurochirurgica*, 164(9), 2453–2464. <https://doi.org/10.1007/s00701-022-05301-y>
10. Barresi, V. (2011). Angiogenesis in meningiomas. In *Brain Tumor Pathology* (Vol. 28, Issue 2, pp. 99–106). <https://doi.org/10.1007/s10014-010-0012-2>
11. Ansari, S. F., Shah, K. J., Hassaneen, W., & Cohen-Gadol, A. A. (2020). *Vascularity of meningiomas* (pp. 153–165). <https://doi.org/10.1016/B978-0-12-804280-9.00010-X>
12. Lamszus, K., Lengler, U., Schmidt, N. O., Stavrou, D., Ergün, S., & Westphal, M. (2000). Vascular Endothelial Growth Factor, Hepatocyte Growth Factor/Scatter factor, Basic Fibroblast Growth Factor, and Placenta Growth Factor in Human meningiomas and Their Relation to Angiogenesis and Malignancy. *Neurosurgery*, 4), 938–948. <https://doi.org/10.1097/00006123-200004000-00033>



13. Ferrara, N., & Davis-Smyth, T. (1997). The Biology of Vascular Endothelial Growth Factor. *Endocrine Reviews*, 18(1), 4–25. <https://doi.org/10.1210/edrv.18.1.0287>
14. Aghili, E., Mahzouni, P., & Sabaghi, B. (2018). An Immunohistochemical Study of Vascular Endothelial Growth Factor Expression in Meningioma and Its Correlation with Tumor Grade. In *Middle East Journal of Cancer* (Vol. 9, Issue 4).
15. Sakuma, T., Nakagawa, T., Ido, K., Takeuchi, H., Sato, K., & Kubota, T. (2008). Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human meningiomas. *Journal of Neuro-Oncology*, 88(2), 143–155. <https://doi.org/10.1007/s11060-008-9559-8>
16. Pistolesi, S., Boldrini, L., Gisfredi, S., Ieso, K. de, Camacci, T., Caniglia, M., Lupi, G., Leocata, P., Basolo, F., Pingitore, R., Parenti, G., & Fontanini, G. (2004). Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. *Neuropathology and Applied Neurobiology*, 30(2), 118–125. <https://doi.org/10.1046/j.0305-1846.2003.00516.x>
17. Ruiz, J., Martínez, A., Hernández, S., Zimman, H., Ferrer, M., Fernández, C., Sáez, M., López-Asenjo, J. A., & Sanz-Ortega, J. (2010). Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II. *Histology and Histopathology*, 25(3), 341–349. <https://doi.org/10.14670/HH-25.341>
18. Richard, W. H. (2017). *Youmans and Winn Neurological Surgery*. 7th Ed. Philadelphia, PA : Elsevier
19. Moliterno, J., & Omuro, A. (2020). *Meningioma Comprehensive Strategies for Management*. <https://doi.org/https://doi.org/10.1007/978-3-030-59558-6>
20. McDermott, M. W., & Al-Mefty, O. (2011). *Al-Mefty's Meningiomas Second Edition*.
21. Harter, P. N., Braun, Y., & Plate, K. H. (2017). Classification of meningiomas—advances and controversies. In *Chinese Clinical Oncology* (Vol. 6). AME Publishing Company. <https://doi.org/10.21037/cco.2017.05.02>
22. Vernooij, M. W., Ikram, M. A., Tanghe, H. L., Vincent, A. J. P. E., Hofman, A., Krestin, G. P., Niessen, W. J., Breteler, M. M. B., & van der Lugt, A. (2007). Incidental Findings on Brain MRI in the General Population. *New England Journal of Medicine*, 357(18), 1821–1828. <https://doi.org/10.1056/NEJMoa070972>
23. Nakasu, S., Hirano, A., Shimura, T., & Llena, J. F. (1987). Incidental meningiomas in autopsy study. *Surgical Neurology*, 27(4), 319–322. [https://doi.org/10.1016/0090-3019\(87\)90005-X](https://doi.org/10.1016/0090-3019(87)90005-X)
24. Preston, D. L. (2002). Tumors of the Nervous System and Pituitary Gland Associated With Atomic Bomb Radiation Exposure. *CancerSpectrum Knowledge Environment*, 94(20), 1555–1563. <https://doi.org/10.1093/jnci/94.20.1555>
25. Longstreth, W. T., Phillips, L. E., Drangsholt, M., Koepsell, T. D., Custer, B. S., Gehrels, J., & van Belle, G. (2004). Dental X-rays and the risk of intracranial meningioma. *Cancer*, 100(5), 1026–1034. <https://doi.org/10.1002/cncr.20036>
26. Ron, E., Modan, B., Boice, J. D., Alfandary, E., Stovall, M., Chetrit, A., & Katz, L. (1988). Tumors of the Brain and Nervous System after Radiotherapy in Childhood. *New England Journal of Medicine*, 319(16), 1033–1039. <https://doi.org/10.1056/NEJM198810203191601>
27. Tanaka, R., Hayano, A., & Kanayama, T. (2017). Radiation-Induced meningiomas: An Exhaustive Review of the Literature. *World Neurosurgery*, 97, 644.e8. <https://doi.org/10.1016/j.wneu.2016.09.094>



28. Agnihotri, S., Suppiah, S., Tonge, P. D., Jalali, S., Danesh, A., Bruce, J. P., Mamatjan, Y., Klironomos, G., Gonen, L., Au, K., Mansouri, S., Karimi, S., Sahm, F., von Deimling, A., Taylor, M. D., Laperriere, N. J., Pugh, T. J., Aldape, K. D., & Zadeh, G. (2017). Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. *Nature Communications*, 8(1), 186. <https://doi.org/10.1038/s41467-017-00174-7>
29. Claus, E. B., Black, P. M., Bondy, M. L., Calvocoressi, L., Schildkraut, J. M., Wiemels, J. L., & Wrensch, M. (2007). Exogenous hormone use and meningioma risk. *Cancer*, 110(3), 471–476. <https://doi.org/10.1002/cncr.22783>
30. Claus, E. B., Park, P. J., Carroll, R., Chan, J., & Black, P. M. (2008). Specific Genes Expressed in Association with Progesterone Receptors in Meningioma. *Cancer Research*, 68(1), 314–322. <https://doi.org/10.1158/0008-5472.CAN-07-1796>
31. Blitshteyn, S., Crook, J. E., & Jaeckle, K. A. (2008). Is There an Association Between Meningioma and Hormone Replacement Therapy? *Journal of Clinical Oncology*, 26(2), 279–282. <https://doi.org/10.1200/JCO.2007.14.2133>
32. Jhawar, B. S., Fuchs, C. S., Colditz, G. A., & Stampfer, M. J. (2003). Sex steroid hormone exposures and risk for meningioma. *Journal of Neurosurgery*, 99(5), 848–853. <https://doi.org/10.3171/jns.2003.99.5.0848>
33. Benson, V. S., Pirie, K., Green, J., Casabonne, D., & Beral, V. (2008). Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. *British Journal of Cancer*, 99(1), 185–190. <https://doi.org/10.1038/sj.bjc.6604445>
34. Inskip, P. D., Mellekjaer, L., Gridley, G., & Olsen, J. H. (1998). Incidence of intracranial tumors following hospitalization for head injuries (Denmark). *Cancer Causes and Control*, 9(1), 109–116. <https://doi.org/10.1023/A:1008861722901>
35. Kuan, A.-S., Chen, Y.-T., Teng, C.-J., Wang, S.-J., & Chen, M.-T. (2014). Risk of meningioma in patients with head injury: A nationwide population-based study. *Journal of the Chinese Medical Association*, 77(9), 457–462. <https://doi.org/10.1016/j.jcma.2014.06.005>
36. Bethke, L., Murray, A., Webb, E., Schoemaker, M., Muir, K., McKinney, P., Hepworth, S., Dimitropoulou, P., Lophatananon, A., Feychting, M., Lönn, S., Ahlbom, A., Malmer, B., Henriksson, R., Auvinen, A., Kiuru, A., Salminen, T., Johansen, C., Christensen, H. C., ... Houlston, R. (2008). Comprehensive Analysis of DNA Repair Gene Variants and Risk of Meningioma. *JNCI: Journal of the National Cancer Institute*, 100(4), 270–276. <https://doi.org/10.1093/jnci/djn004>
37. Samii, M., & Gerganov, V. (2013). Meningiomas. In *Surgery of Cerebellopontine Lesions* (pp. 375–507). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-35422-9_7
38. Malmer, B., Henriksson, R., & Grönberg, H. (2003). Familial brain tumours—genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients. *International Journal of Cancer*, 106(2), 260–263. <https://doi.org/10.1002/ijc.11213>
39. Manki, K., Tretli, S., Sundquist, J., Johannesen, T. B., & Granström, C. (2009). Familial risks in nervous-system tumours: a histology-specific analysis in Sweden and Norway. *The Lancet Oncology*, 10(5), 481–488. [https://doi.org/10.1016/S1470-2045\(09\)70076-2](https://doi.org/10.1016/S1470-2045(09)70076-2)



40. Shankar, G. M., Abedalthagafi, M., Vaubel, R. A., Merrill, P. H., Nayyar, N., Gill, C. M., Brewster, R., Bi, W. L., Agarwalla, P. K., Thorner, A. R., Reardon, D. A., Al-Mefty, O., Wen, P. Y., Alexander, B. M., van Hummelen, P., Batchelor, T. T., Ligon, K. L., Ligon, A. H., Meyerson, M., ... Santagata, S. (2016). Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. *Neuro-Oncology*, now235. <https://doi.org/10.1093/neuonc/now235>
41. Keppler-Noreuil, K. M., Baker, E. H., Sapp, J. C., Lindhurst, M. J., & Biesecker, L. G. (2016). Somatic *AKT1* mutations cause meningiomas colocalizing with a characteristic pattern of cranial hyperostosis. *American Journal of Medical Genetics Part A*, 170(10), 2605–2610. <https://doi.org/10.1002/ajmg.a.37737>
42. Riant, F., Bergametti, F., Fournier, H.-D., Chapon, F., Michalak-Provost, S., Cecillon, M., Lejeune, P., Hosseini, H., Choe, C., Orth, M., Bernreuther, C., Boulday, G., Denier, C., Labauge, P., & Tournier-Lasserre, E. (2013). CCM3 Mutations Are Associated with Early-Onset Cerebral Hemorrhage and Multiple Meningiomas. *Molecular Syndromology*, 4(4), 165–172. <https://doi.org/10.1159/000350042>
43. Zadeh, G., Goldbrunner, R., Krischek, B., & Nassiri, F. (2023). Biological and Clinical Landscape of Meningiomas (G. Zadeh, R. Goldbrunner, B. Krischek, & F. Nassiri, Eds.; Vol. 1416). Springer International Publishing. <https://doi.org/10.1007/978-3-031-29750-2>
44. Tanti, M. J., Marson, A. G., & Jenkinson, M. D. (2017). Epilepsy and adverse quality of life in surgically resected meningioma. *Acta Neurologica Scandinavica*, 136(3), 246–253. <https://doi.org/10.1111/ane.12711>
45. Englot, D. J., Magill, S. T., Han, S. J., Chang, E. F., Berger, M. S., & McDermott, M. W. (2016). Seizures in supratentorial meningioma: a systematic review and meta-analysis. *Journal of Neurosurgery*, 124(6), 1552–1561. <https://doi.org/10.3171/2015.4.JNS142742>
46. Beaumont, A., & Whittle, I. R. (2000). The Pathogenesis of Tumour Associated Epilepsy. *Acta Neurochirurgica*, 142(1), 1–15. <https://doi.org/10.1007/s007010050001>
47. Kawaguchi, T., Kameyama, S., & Tanaka, R. (1996). Peritumoral Edema and Seizure in Patients with Cerebral Convexity and Parasagittal Meningiomas. *Neurologia Medico-Chirurgica*, 36(8), 568–574. <https://doi.org/10.2176/nmc.36.568>
48. Islim, A. I., McKeever, S., Kusu-Orkar, T.-E., & Jenkinson, M. D. (2017). The role of prophylactic antiepileptic drugs for seizure prophylaxis in meningioma surgery: A systematic review. *Journal of Clinical Neuroscience*, 43, 47–53. <https://doi.org/10.1016/j.jocn.2017.05.020>
49. Kahn, K., & Finkel, A. (2014). It IS a Tumor- Current Review of Headache and Brain Tumor. *Current Pain and Headache Reports*, 18(6), 421. <https://doi.org/10.1007/s11916-014-0421-8>
50. Freeman, W. D. (2015). Management of Intracranial Pressure. *CONTINUUM: Lifelong Learning in Neurology*, 21, 1299–1323. <https://doi.org/10.1212/CON.0000000000000235>
51. Skal, I., Gehring, K., Rutten, G.-J. M., & Sitskoorn, M. M. (2016). Cognitive functioning in meningioma patients: a systematic review. *Journal of Neurology*, 128(2), 195–205. <https://doi.org/10.1007/s11060-016-2115-z>



52. Gyawali, S., Sharma, P., & Mahapatra, A. (2019). Meningioma and psychiatric symptoms: An individual patient data analysis. *Asian Journal of Psychiatry*, 42, 94–103. <https://doi.org/10.1016/j.ajp.2019.03.029>
53. Schneider, M., Schuss, P., Güresir, Á., Wach, J., Hamed, M., Vatter, H., & GÜresir, E. (2019). Cranial Nerve Outcomes After Surgery for Frontal Skull Base Meningiomas: The Eternal Quest of the Maximum-Safe Resection with the Lowest Morbidity. *World Neurosurgery*, 125, e790–e796. <https://doi.org/10.1016/j.wneu.2019.01.171>
54. Faramand, A., Kano, H., Niranjana, A., Johnson, S. A., Hassib, M., Park, K.-J., Arai, Y., Flickinger, J. C., & Lunsford, L. D. (2018). Cranial nerve outcomes after primary stereotactic radiosurgery for symptomatic skull base meningiomas. *Journal of Neuro-Oncology*, 139(2), 341–348. <https://doi.org/10.1007/s11060-018-2866-9>
55. Greenberg, M. S. (2023). *Handbook of Neurosurgery 10th Edition*. i
56. Wayhs, S. Y., Lepski, G. A., Frighetto, L., & Isolan, G. R. (2017). Petroclival meningiomas: Remaining controversies in light of minimally invasive approaches. *Clinical Neurology and Neurosurgery*, 152, 68–75. <https://doi.org/10.1016/j.clineuro.2016.11.021>
57. Raghunathan, A., & Giannini, C. (2023). Histopathology of Meningiomas. In In G. Zadeh, R. Goldbrunner, B. Krischek, & F. Nassiri (Eds.), *Biological and Clinical Landscape of Meningiomas* (pp. 35–45). Springer. https://doi.org/10.1007/978-3-031-29750-2_4
58. Hirota, S., Nakajima, Y., Yoshimine, T., Kohri, K., Nomura, S., Taneda, M., Hayakawa, T., & Kitamura, Y. (1995). Expression of Bone-related Protein Messenger RNA in Human Meningiomas: Possible Involvement of Osteopontin in Development of Psammoma Bodies. *Journal of Neuropathology and Experimental Neurology*, 54(5), 698–703. <https://doi.org/10.1097/00005072-199509000-00012>
59. Hua, L., Luan, S., Li, H., Zhu, H., Tang, H., Liu, H., Chen, X., Bozinov, O., Xie, Q., & Gong, Y. (2017). Angiomatous Meningiomas Have a Very Benign Outcome Despite Frequent Peritumoral Edema at Onset. *World Neurosurgery*, 108, 465–473. <https://doi.org/10.1016/j.wneu.2017.08.096>
60. Çolakoğlu, N. (2003). Secretory Meningioma. *Journal of Neuro-Oncology*, 62(3), 233–241. <https://doi.org/10.1023/A:1023319407645>
61. Buhl, R., Hugo, H.-H., & Mehdorn, H. M. (2001). Brain oedema in secretory meningiomas. *Journal of Clinical Neuroscience*, 8(4), 19–21. <https://doi.org/10.1054/jocn.2001.0871>
62. Bruno, M. C., Ginguen , C., Santangelo, M., Panagiotopoulos, K., Piscopo, G. A., Tortora, F., Elefante, A., de Caro, M. L., & Cerillo, A. (2004). Lymphoplasmacyte rich meningioma. A case report and review of the literature. *Journal of Neurosurgical Sciences*, 48(3), 117–124; discussion 124.
63. Zhu, H.-D., Xie, Q., Gong, Y., Mao, Y., Zhong, P., Hang, F.-P., Chen, H., Zheng, M.-Z., Tang, H.-L., Wang, D.-J., Chen, X.-C., & Zhou, L.-F. (2013). Lymphoplasmacyte-rich meningioma: our experience with 19 cases and a thematic literature review. *International Journal of Clinical and Experimental Medicine*, 6(7), 504–515.
64. Caroli, F., Scheithauer, B. W., Laeng, R. H., Cenacchi, G., Abell-Aleff, P., & Schopulos, M. (2001). Lipomatous Meningioma. *The American Journal of*



- Surgical Pathology*, 25(6), 769–775. <https://doi.org/10.1097/00000478-200106000-00008>
65. Perry, A., Scheithauer, B. W., Stafford, S. L., Lohse, C. M., & Wollan, P. C. (1999). “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. *Cancer*, 85(9), 2046–2056. [https://doi.org/10.1002/\(SICI\)1097-0142\(19990501\)85:9<2046::AID-CNCR23>3.0.CO;2-M](https://doi.org/10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M)
 66. Bale, T. A., Benhamida, J., Roychoudury, S., Villafania, L., Wrzolek, M. A., Bouffard, J.-P., Bapat, K., Ladanyi, M., & Rosenblum, M. K. (2020). Infarction with associated pseudosarcomatous changes mimics anaplasia in otherwise grade I meningiomas. *Modern Pathology*, 33(7), 1298–1306. <https://doi.org/10.1038/s41379-020-0491-6>
 67. Marciscano, A. E., Stemmer-Rachamimov, A. O., Niemierko, A., Larvie, M., Curry, W. T., Barker, F. G., Martuza, R. L., McGuone, D., Oh, K. S., Loeffler, J. S., & Shih, H. A. (2016). Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. *Journal of Neurosurgery*, 124(1), 106–114. <https://doi.org/10.3171/2015.1.JNS142228>
 68. Zorludemir, S., Scheithauer, B. W., Hirose, T., van Houten, C., Miller, G., & Meyer, F. B. (1995). Clear cell meningioma. A clinicopathologic study of a potentially aggressive variant of meningioma. *The American Journal of Surgical Pathology*, 19(5), 493–505.
 69. Tauziède-Espariat, A., Parfait, B., Besnard, A., Lacombe, J., Pallud, J., Tazi, S., Puget, S., Lot, G., Terris, B., Cohen, J., Vidaud, M., Figarella-Branger, D., Monnier, F., Polivka, M., Adle-Biassette, H., & Varlet, P. (2018). Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis. *Brain Pathology*, 28(4), 466–474. <https://doi.org/10.1111/bpa.12524>
 70. Couce, M. E., Aker, F. v., & Scheithauer, B. W. (2000). Chordoid Meningioma. *The American Journal of Surgical Pathology*, 24(7), 899–905. <https://doi.org/10.1097/00000478-200007000-00001>
 71. Kepes, J. J., Chen, W. Y.-K., Connors, M. H., & Vogel, F. S. (1988). “Chordoid” meningeal tumors in young individuals with peritumoral lymphoplasmacellular infiltrates causing systemic manifestations of the castleman syndrome. A report of seven cases. *Cancer*, 62(2), 391–406. [https://doi.org/10.1002/1097-0142\(19880715\)62:2<391::AID-CNCR2820620226>3.0.CO;2-7](https://doi.org/10.1002/1097-0142(19880715)62:2<391::AID-CNCR2820620226>3.0.CO;2-7)
 72. Perry, A., Scheithauer, B. W., Stafford, S. L., Abell-Aleff, P. C., & Meyer, F. B. (1998). “Rhabdoid” Meningioma. *The American Journal of Surgical Pathology*, 22(12), 1482–1490. <https://doi.org/10.1097/00000478-199812000-00005>
 73. Vaubel, R. A., Chen, S. G., Raleigh, D. R., Link, M. J., Chicoine, M. R., Barani, I., Jenkins, S. M., Aleff, P. A., Rodriguez, F. J., Burger, P. C., Dahiya, S., Perry, A., & Giannini, C. (2016). Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature. *Journal of Neuropathology & Experimental Neurology*, 75(1), 44–52. <https://doi.org/10.1093/jnen/nlv006>
 74. Swin, S. K., Rubinstein, L. J., & Russell, D. S. (1975). Papillary meningioma: A malignant variant of meningioma. *Cancer*, 36(4), 1363–1373. [https://doi.org/10.1002/1097-0142\(197510\)36:4<1363::AID-CR2820360427>3.0.CO;2-Z](https://doi.org/10.1002/1097-0142(197510)36:4<1363::AID-CR2820360427>3.0.CO;2-Z)



75. Danish, H., & Brastianos, P. (2023). Novel Medical Therapies in Meningiomas. In G. Zadeh, R. Goldbrunner, B. Krischek, & F. Nassiri (Eds.), *Biological and Clinical Landscape of Meningiomas*, (pp. 213–223). https://doi.org/10.1007/978-3-031-29750-2_16
76. Ragel, B. T., & Jensen, R. L. (2005). Molecular genetics of meningiomas. *Neurosurgical Focus*, 19(5), 1–8. <https://doi.org/10.3171/foc.2005.19.5.10>
77. Akagi, K., Kurahashi, H., Arita, N., Hayakawa, T., Monden, M., Mori, T., Takai, S., & Nishisho, I. (1995). Deletion mapping of the long arm of chromosome 22 in human meningiomas. *International Journal of Cancer*, 60(2), 178–182. <https://doi.org/10.1002/ijc.2910600208>
78. Kalamirides, M., Niwa-Kawakita, M., Leblais, H., Abramowski, V., Perricaudet, M., Janin, A., Thomas, G., Gutmann, D. H., & Giovannini, M. (2002). Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. *Genes & Development*, 16(9), 1060–1065. <https://doi.org/10.1101/gad.226302>
79. Bello, M. J., Pestaña, A., Rey, J. A., de Campos, J. M., Kusak, M. E., Vaquero, J., & Sarasay, J. L. (1994). Allelic loss at 1 p is associated with tumor progression of meningiomas. *Genes, Chromosomes and Cancer*, 9(4), 296–298. <https://doi.org/10.1002/gcc.2870090411>
80. Ketter, R., Henn, W., Niedermayer, I., Steilen-Gimbel, H., König, J., Zang, K. D., & Steudel, W.-I. (2001). Predictive value of progression-associated chromosomal aberrations for the prognosis of meningiomas: a retrospective study of 198 cases. *Journal of Neurosurgery*, 95(4), 601–607. <https://doi.org/10.3171/jns.2001.95.4.0601>
81. Detta, A., Kenny, B. G., Smith, C., Logan, A., & Hitchcock, E. (1993). Correlation of Proto-oncogene Expression and Proliferation in Meningiomas. *Neurosurgery*, 33(6), 1065–1074. <https://doi.org/10.1227/00006123-199312000-00015>
82. Zhao, J.-F., & Sharma, S. (1995). Expression of the ROS1 oncogene for tyrosine receptor kinase in adult human meningiomas. *Cancer Genetics and Cytogenetics*, 83(2), 148–154. [https://doi.org/10.1016/0165-4608\(95\)00043-O](https://doi.org/10.1016/0165-4608(95)00043-O)
83. Ragel, B. T., & Jensen, R. L. (2003). Pathophysiology of Meningiomas. *Seminars in Neurosurgery*, 14(3), 169–186. <https://doi.org/10.1055/s-2004-817734>
84. Linggood, R. M., Hsu, D. W., Efrid, J. T., & Pardo, F. S. (1995). TGF alpha expression in meningioma: tumor progression and therapeutic response. *Journal of Neuro-Oncology*, 26(1), 45–51. <https://doi.org/10.1007/BF01054768>
85. Jensen, R. L., Lee, Y. S., Gujirati, M., Origitano, T. C., Wurster, R. D., & Reichman, O. H. (1995). Inhibition of In Vitro Meningioma Proliferation after Growth Factor Stimulation by Calcium Channel Antagonists. *Neurosurgery*, 37(5), 937–947. <https://doi.org/10.1227/00006123-199511000-00013>
86. Todo, T., Adams, E. F., Fahlbusch, R., Dingermann, T., & Werner, H. (1996). Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. *Journal of Neurosurgery*, 84(5), 852–858. <https://doi.org/10.3171/jns.1996.84.5.0852>
87. Chalk, R. P., Gettleman, R., Patel, K., Lakshman, R., & Tsibris, J. C. M. (1989). Somatostatin, Somatostatin Receptor, and Insulin-Like Growth Factor I in Brain Tumors: Binding and in Vitro Effects. *Neurosurgery*, 24(6), 791–797. <https://doi.org/10.1227/00006123-199006000-00001>
88. Schulz, S., Pauli, S. U., Schulz, S., Händel, M., Dietzmann, K., Firsching, R., & Lötters, V. (2000). Immunohistochemical determination of five somatostatin



receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, 6(5), 1865–1874.

89. García-Luna, P. P., Relimpio, F., Pumar, A., Pereira, J. L., Leal-Cerro, A., Trujillo, F., Cortés, A., & Astorga, R. (1993). Clinical use of octreotide in unresectable meningiomas. A report of three cases. *Journal of Neurosurgical Sciences*, 37(4), 237–241.
90. Jensen, R. L., Soleau, S., Bhayani, M. K., & Christiansen, D. (2002). Expression of hypoxia inducible factor—1 alpha and correlation with preoperative embolization of meningiomas. *Journal of Neurosurgery*, 97(3), 658–667. <https://doi.org/10.3171/jns.2002.97.3.0658>
91. Kim, B.-W., Kim, M.-S., Kim, S.-W., Chang, C.-H., & Kim, O.-L. (2011). Peritumoral Brain Edema in Meningiomas: Correlation of Radiologic and Pathologic Features. *Journal of Korean Neurosurgical Society*, 49(1), 26. <https://doi.org/10.3340/jkns.2011.49.1.26>
92. Hou, J., Kshetry, V. R., Selman, W. R., & Bambakidis, N. C. (2013). Peritumoral brain edema in intracranial meningiomas: the emergence of vascular endothelial growth factor-directed therapy. *Neurosurgical Focus*, 35(6), E2. <https://doi.org/10.3171/2013.8.FOCUS13301>
93. Dellian, M., Witwer, B. P., Salehi, H. A., Yuan, F., & Jain, R. K. (1996). Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. *The American Journal of Pathology*, 149(1), 59–71.
94. Pekala, P., Marlow, M., Heuvelman, D., & Connolly, D. (1990). Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin. *The Journal of Biological Chemistry*, 265(30), 18051–18054.
95. Melder, R. J., Koenig, G. C., Witwer, B. P., Safabakhsh, N., Munn, L. L., & Jain, R. K. (1996). During angiogenesis, vascular endothelial growth factor regulate natural killer cell adhesion to tumor endothelium. *Nature Medicine*, 2(9), 992–997. <https://doi.org/10.1038/nm0996-992>
96. Gabilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996). Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. *Nature Medicine*, 2(10), 1096–1103. <https://doi.org/10.1038/nm1096-1096>
97. Maiuri, F., de Caro, M. D. B., Esposito, F., Cappabianca, P., Strazzullo, V., Pettinato, G., & de Divitiis, E. (2007). Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. *Journal of Neuro-Oncology*, 82(1), 63–68. <https://doi.org/10.1007/s11060-005-9078-9>
98. Barresi, V., & Tuccari, G. (2010). Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas. *Neuropathology*, 30(5), 537–546. <https://doi.org/10.1111/j.1440-0929.2010.01105.x>
99. Li, H.-Q., Soker, S., Feiner, L., Alonso, J. L., Raper, J. A., & Klagsbrun, M. (1999). Neuropilin-1 Mediates Collapsin-1/Semaphorin III Inhibition of Endothelial Cell Motility. *The Journal of Cell Biology*, 146(1), 233–242. <https://doi.org/10.1083/jcb.146.1.233>



100. Luo, Y., Raible, D., & Raper, J. A. (1993). Collapsin: A protein in brain that induces the collapse and paralysis of neuronal growth cones. *Cell*, 75(2), 217–227. [https://doi.org/10.1016/0092-8674\(93\)80064-L](https://doi.org/10.1016/0092-8674(93)80064-L)
101. Guttman-Raviv, N., Shraga-Heled, N., Varshavsky, A., Guimaraes-Sternberg, C., Kessler, O., & Neufeld, G. (2007). Semaphorin-3A and Semaphorin-3F Work Together to Repel Endothelial Cells and to Inhibit Their Survival by Induction of Apoptosis. *Journal of Biological Chemistry*, 282(36), 26294–26305. <https://doi.org/10.1074/jbc.M609711200>
102. Soker, S., Miao, H., Nomi, M., Takashima, S., & Klagsbrun, M. (2002). VEGF 165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF 165 -receptor binding. *Journal of Cellular Biochemistry*, 85(2), 357–368. <https://doi.org/10.1002/jcb.10140>
103. Barresi, V., Vitarelli, E., & Cerasoli, S. (2009). Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density. *Virchows Archiv*, 454(5), 563–571. <https://doi.org/10.1007/s00428-009-0757-3>
104. Vermeulen, P. B., Gasparini, G., Fox, S. B., Colpaert, C., Marson, L. P., Gion, M., Beliën, J. A. M., de Waal, R. M. W., van Marck, E., Magnani, E., Weidner, N., Harris, A. L., & Dirix, L. Y. (2002). Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. *European Journal of Cancer*, 38(12), 1564–1579. [https://doi.org/10.1016/S0959-8049\(02\)00094-1](https://doi.org/10.1016/S0959-8049(02)00094-1)
105. Jensen, R., & Lee, J. (2012). Predicting Outcomes of Patients With Intracranial Meningiomas Using Molecular Markers of Hypoxia, Vascularity, and Proliferation. *Neurosurgery*, 71(1), 146–156. <https://doi.org/10.1227/NEU.0b013e3182567886>
106. Wu, Y., Lucia, K., Lange, M., Kuhlen, D., Stalla, G. K., & Renner, U. (2014). Hypoxia inducible factor-1 is involved in growth factor, glucocorticoid and hypoxia mediated regulation of vascular endothelial growth factor-A in human meningiomas. *Journal of Neuro-Oncology*, 119(2), 263–273. <https://doi.org/10.1007/s11060-014-1503-5>
107. Barresi, V., Cerasoli, S., & Tuccari, G. (2008). Correlative evidence that tumor cell-derived caveolin-1 mediates angiogenesis in meningiomas. *Neuropathology*, 28(5), 472–478. <https://doi.org/10.1111/j.1440-1789.2008.00902.x>
108. Boldrini, L., Pistolesi, S., Gisfredi, S., Ursino, S., Ali, G., Pieracci, N., Basolo, F., Parenti, G., & Fontanini, G. (2006). Expression of endothelin 1 and its angiogenic role in meningiomas. *Virchows Archiv*, 449(5), 546–553. <https://doi.org/10.1007/s00428-006-0273-7>
109. Braun, B., Lange, M., Oeckler, R., & Mueller, M. M. (2004). Expression of G-CSF and GM-CSF in Human Meningiomas Correlates with Increased Tumor Proliferation and Vascularization. *Journal of Neuro-Oncology*, 68(2), 131–140. <https://doi.org/10.1023/B:NEON.0000027751.87894.f0>
110. Ogasawara, C., Philbrick, B. D., & Adamson, D. C. (2021). Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Perspectives. *Biomedicines*, 9(3), 319. <https://doi.org/10.3390/biomedicines9030319>
111. Gupta, A., Bir, S. C., Maiti, T. K., Konar, S. K., Missios, S., & Guthikonda, B. (2017). Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma. *Journal of Neurosurgery*, 126(1), 201–211. <https://doi.org/10.3171/2016.1.JNS151842>



112. Gunadi, S. V., Suryanti, S., & Yohana, R. (2018). The Distribution of Meningioma in Dr. Hasan Sadikin General Hospital Bandung Period 2010–2013. *Althea Medical Journal*, 5(3), 157–160. <https://doi.org/10.15850/amj.v5n3.1062>
113. Pereira, B. J. A., Oba-Shinjo, S. M., de Almeida, A. N., & Marie, S. K. N. (2019). Molecular alterations in meningiomas: Literature review. *Clinical Neurology and Neurosurgery*, 176, 89–96. <https://doi.org/10.1016/j.clineuro.2018.12.004>
114. Pieper, D. R., Al-Mefty, O., Hanada, Y., & Buechner, D. (1999). Hyperostosis Associated with Meningioma of the Cranial Base: Secondary Changes or Tumor Invasion. *Neurosurgery*, 44(4), 742–746. <https://doi.org/10.1097/00006123-199904000-00028>
115. Somerset, H. L., Kleinschmidt-DeMasters, B. K., Rubinstein, D., & Breeze, R. E. (2010). Osteochondroma of the convexity: pathologic-neuroimaging correlates of a lesion that mimics high-grade meningioma. *Journal of Neuro-Oncology*, 98(3), 421–426. <https://doi.org/10.1007/s11060-009-0089-9>
116. Guermazi, A., Lafitte, F., Miaux, Y., Adem, C., Bonneville, J.-F., & Chiras, J. (2005). The dural tail sign—beyond meningioma. *Clinical Radiology*, 60(2), 171–188. <https://doi.org/10.1016/j.crad.2004.01.019>
117. Khu, K. J., Ng, I., & Ng, W. H. (2009). The relationship between parasagittal and falxine meningiomas and the superficial cortical veins: a virtual reality study. *Acta Neurochirurgica*, 151(11), 1459–1464. <https://doi.org/10.1007/s00701-009-0379-1>
118. Vignes, J. R., Sesay, M., Rezajooi, K., Gimbert, E., & Liguoro, D. (2008). Peritumoral edema and prognosis in intracranial meningioma surgery. *Journal of Clinical Neuroscience*, 15(7), 764–768. <https://doi.org/10.1016/j.jocn.2007.06.001>
119. İldan, F., Erman, T., Göçer, A., Tuna, M., Bağdatoğlu, H., Çetinalp, E., & Burgut, R. (2007). Predicting the Probability of Meningioma Recurrence in the Preoperative and Early Postoperative Period: A Multivariate Analysis in the Midterm Follow-Up. *Skull Base*, 17(3), 157–171. <https://doi.org/10.1055/s-2007-970554>
120. Hayward, R. (2003). VOMIT (victims of modern imaging technology)--an acronym for our times. *BMJ*, 326(7401), 1273–1273. <https://doi.org/10.1136/bmj.326.7401.1273>
121. Goldbrunner, R., Stavrinou, P., Jenkinson, M. D., Sahm, F., Mawrin, C., Weber, D. C., Preusser, M., Minniti, G., Lund-Johansen, M., Lefranc, F., Houdart, E., Sallabanda, K., le Rhun, E., Nieuwenhuizen, D., Tabatabai, G., Soffietti, R., & Weller, M. (2021). EANO guideline on the diagnosis and management of meningiomas. *Neuro-Oncology*, 23(11), 1821–1834. <https://doi.org/10.1093/neuonc/noab150>
122. Nakasu, S., Fukami, T., Nakajima, M., Watanabe, K., Ichikawa, M., & Matsuda, M. (2005). Growth pattern changes of meningiomas: long-term analysis. *Neurosurgery*, 56(5), 946–955; discussion 946-55.
123. Yano, S., & Kuratsu, J. (2006). Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. *Journal of Neurosurgery*, 105(4), 538–543. <https://doi.org/10.3171/jns.2006.105.4.538>
124. Simpson, D. (1957). The recurrence of intracranial meningiomas after surgical treatment. *Journal of Neurology, Neurosurgery & Psychiatry*, 20(1), 22–39. <https://doi.org/10.1136/jnnp.20.1.22>



125. Kondziolka, D., Lunsford, L. D., Coffey, R. J., & Flickinger, J. C. (1991). Stereotactic radiosurgery of meningiomas. *Journal of Neurosurgery*, 74(4), 552–559. <https://doi.org/10.3171/jns.1991.74.4.0552>
126. Olar, A., Wani, K. M., Sulman, E. P., Mansouri, A., Zadeh, G., Wilson, C. D., DeMonte, F., Fuller, G. N., & Aldape, K. D. (2015). Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma. *Brain Pathology*, 25(3), 266–275. <https://doi.org/10.1111/bpa.12174>
127. Notoatmodjo S. (2010.). *Metodologi penelitian kesehatan*. Jakarta : Rineka Cipta.
128. Al-'abqary, R., Widodo, D., Ihwan, A., Bahar, B., Islam, A. A., Mustamir, N., Adhimarta, W., Wahyudi, W., Cangara, M. H., & Faruk, M. (2024). Correlation of the expression of Ki-67 with the histopathological features and grade of meningioma. *Chirurgia*, 37(2). <https://doi.org/10.23736/S0394-9508.23.05558-4>
129. Sitanggang, I. J., Sriwidyani, N. P., Sumadi, I. W. J., Dewi, I. G. A. S. M., Maker, L. P. I. I., & Muliarta, I. M. (2021). Perbedaan ekspresi Vascular Endothelial Growth Factor (VEGF) pada meningioma risiko rendah dan risiko tinggi di RSUP Sanglah, Bali, Indonesia. *Intisari Sains Medis*, 12(2), 557–562. <https://doi.org/10.15562/ism.v12i2.1027>
130. Winter, R. C., Antunes, A. C. M., & Oliveira, F. H. de. (2020). The relationship between vascular endothelial growth factor and histological grade in intracranial meningioma. *Surgical Neurology International*, 11, 328. https://doi.org/10.25259/SNI_528_2020
131. Samoto, K., Ikezaki, K., Ono, M., Shono, T., Kohno, K., Kuwano, M., & Fukui, M. (1995). Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. *Cancer Research*, 55(5), 1189–1193.
132. Ding, Y.-S., Wang, H.-D., Tang, K., Hu, Z.-G., Jin, W., & Yan, W. (2008). Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas. *Annals of Clinical and Laboratory Science*, 38(4), 344–351.
133. Brustmann, H., & Naudé, S. (2002). Vascular Endothelial Growth Factor Expression in Serous Ovarian Carcinoma: Relationship with High Mitotic Activity and High FIGO Stage. *Gynecologic Oncology*, 84(1), 47–52. <https://doi.org/10.1006/gyno.2001.6467>
134. Go, K.-O., & Kim, Y. Z. (2023). Brain Invasion and Trends in Molecular Research on Meningioma. *Brain Tumor Research and Treatment*, 11(1), 47. <https://doi.org/10.14791/btrt.2022.0044>
135. Sindou, M., & Alaywan, M. (1994). Role of pia mater vascularization of the tumour in the surgical outcome of intracranial meningiomas. *Acta Neurochirurgica*, 130(1–4), 90–93. <https://doi.org/10.1007/BF01405507>
136. Rana, R., Sharma, S., & Ganguly, N. K. (2021). Comprehensive overview of extracellular vesicle proteomics in meningioma: future strategy. *Molecular Biology Reports*, 48(12), 8061–8074. <https://doi.org/10.1007/s11033-021-06740-z>
137. t, D. J., & van Meir, E. G. (2001). Glomeruloid microvascular proliferation hestrated by VPF/VEGF: a new world of angiogenesis research. *The erican Journal of Pathology*, 158(3), 789–796. [https://doi.org/10.1016/S0002-10\(10\)64025-4](https://doi.org/10.1016/S0002-10(10)64025-4)



138. Lee, Y. S., & Lee, Y. S. (2020). Molecular characteristics of meningiomas. *Journal of Pathology and Translational Medicine*, 54(1), 45–63. <https://doi.org/10.4132/jptm.2019.11.05>
139. Reszec, J., Hermanowicz, A., Rutkowski, R., Turek, G., Mariak, Z., & Chyczewski, L. (2015). Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema. *BioMed Research International*, 2015, 646853. <https://doi.org/10.1155/2015/646853>
140. Duffy AM., Bouchier-Hayes DJ., Harmey JH. Vascular Endothelial Growth Factor (VEGF) and Its Role in Non-Endothelial Cells: Autocrine Signalling by VEGF. In: *Madame Curie Bioscience Database [Internet]*. Austin (TX): Landes Bioscience; 2000-2013.
141. Yamasaki, F., Yoshioka, H., Hama, S., Sugiyama, K., Arita, K., & Kurisu, K. (2000). Recurrence of meningiomas. *Cancer*, 89(5), 1102–1110. [https://doi.org/10.1002/1097-0142\(20000901\)89:5<1102::AID-CNCR20>3.0.CO;2-L](https://doi.org/10.1002/1097-0142(20000901)89:5<1102::AID-CNCR20>3.0.CO;2-L)

